Adaptive Phage Therapeutics Appoints Edward Fang as Chief Medical Officer

October 25, 2022

News, Press Releases

Comments Off on Adaptive Phage Therapeutics Appoints Edward Fang as Chief Medical Officer

GAITHERSBURG, MD, October 25, 2022 – Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company advancing a phage bank, the world’s largest therapeutic phage initiative for treatment of bacterial infectious diseases, today announced the appointment of Edward Fang, M.D. as Chief Medical Officer. Dr. Fang’s responsibilities include overseeing clinical development for APT phage bank treatment candidates through […]

Adaptive Phage Therapeutics Awarded Additional $5 Million from U.S. Defense Health Agency to Support Diabetic Foot Osteomyelitis Clinical Trial

October 4, 2022

News, Press Releases

Comments Off on Adaptive Phage Therapeutics Awarded Additional $5 Million from U.S. Defense Health Agency to Support Diabetic Foot Osteomyelitis Clinical Trial

GAITHERSBURG, MD, October 4, 2022 – Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company advancing the world’s largest therapeutic phage initiative for treatment of bacterial infectious diseases, today announced that the Defense Health Agency (DHA) has awarded an additional $5 million to support clinical development of APT’s adaptive bacteriophage (“phage”) therapy in treatment of diabetic foot […]

Adaptive Phage Therapeutics Announces “The AMR RAPID Challenge” for the Infectious Disease Research Community: Find a Bacteria Resistant to APT’s Investigational Phage Bank

September 7, 2022

News, Press Releases

Comments Off on Adaptive Phage Therapeutics Announces “The AMR RAPID Challenge” for the Infectious Disease Research Community: Find a Bacteria Resistant to APT’s Investigational Phage Bank

GAITHERSBURG, MD, September 7, 2022 – Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company controlling the world’s largest therapeutic phage library initiative and dedicated to providing therapies to treat infectious diseases, today announced “The AMR RAPID™ Challenge” at the World AMR Congress. RAPID is APT’s acronym for Rapidly Adaptive Phage for Infectious Disease. Through this challenge, APT will pay $1,000 to […]

Adaptive Phage Therapeutics Announces First Patient Dosed in the DANCE Trial, a Phase 1/2 Study Evaluating APT Phage Bank in Diabetic Foot Osteomyelitis

May 25, 2022

News, Press Releases

Comments Off on Adaptive Phage Therapeutics Announces First Patient Dosed in the DANCE Trial, a Phase 1/2 Study Evaluating APT Phage Bank in Diabetic Foot Osteomyelitis

GAITHERSBURG, MD, May 17, 2022 – Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the first patient has been dosed in its DFO Adaptive Novel Care Evaluation (DANCE™) trial, a Phase 1/2 clinical study to evaluate the safety and efficacy of APT’s precision bacteriophage (“phage”) therapy in patients with Diabetic Foot Osteomyelitis (DFO). Traditional […]

Infectious disease and the need for more options

June 2, 2020

Featured Stories, News, Press Releases

Comments Off on Infectious disease and the need for more options

By learning from the past, we may have a much better arsenal against antimicrobial-resistant bacteria in the near future.

APT featured in Dutch Broadcast

May 25, 2020

Featured Stories, News, Press Releases

Comments Off on APT featured in Dutch Broadcast

Adaptive Phage Therapeutics was featured in an April 28 broadcast in the Netherlands, Dokters van morgen, discussing the treatment of stubborn infections.  The discussion regarding APT begins at the 35 minute mark and features John Haverty (a patient helped by APT).

A Story of a Virus, Faith, and Hope That Saved His Life with John Haverty

April 2, 2020

Featured Stories, News, Press Releases

Comments Off on A Story of a Virus, Faith, and Hope That Saved His Life with John Haverty

“Never Give Up on Your Life” – John Haverty. John Haverty is a chef, a family man, a patient who was battling a stubborn bacterial infection in his leg for over 10 years.  He wasn’t able to walk and put both feet on the ground for over 10 year.  Doctors at Mayo Clinic were about […]

FDA Clears First Clinical Study for a Polymicrobial Phage Library-Based Treatment for Antibiotic-Resistant Infections

March 12, 2020

Featured Stories, News, Press Releases

Comments Off on FDA Clears First Clinical Study for a Polymicrobial Phage Library-Based Treatment for Antibiotic-Resistant Infections

GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for the clinical development of APT’s phage bank™, a personalized bacteriophage therapeutic for […]

Phages Provide Safety Net In Post-Antibiotic Era

February 13, 2020

Featured Stories, News, Press Releases

Comments Off on Phages Provide Safety Net In Post-Antibiotic Era

February 13, 2020 | To fully appreciate the potential of Adaptive Phage Therapeutics (APT), it’s helpful to review history through the lens of company co-founder and Chief Scientific Officer Carl Merril. For nearly five decades, Carl has been championing the idea of using bacteriophages to treat infectious diseases—an idea for which he has been variably applauded, questioned, ignored, scolded, and, ultimately, vindicated.

Adaptive Phage Therapeutics on NPR

February 11, 2020

Featured Stories, News, Press Releases

Comments Off on Adaptive Phage Therapeutics on NPR

Bacteriophage: A Force Of Nature As bacteria evolve to become more resistant to antibiotics, dangerous infections are taking their toll on human lives. We hear from John Haverty who, after knee replacement surgery generated an unrelenting infection … found himself facing amputation of his leg. Enter a new treatment called ‘phage therapy’ and Greg Merril, […]